42 results about "Degranulation" patented technology

The invention provides a traditional Chinese medicine preparation for treating allergic rhinitis and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from radix asteris, schizonepeta spike, cynanchum paniculatum, perillaseed, spina gleditsiae, cottonrose hibiscus leaf, magnolia flower, semen brassicae, cortex lycii radicis, dendrobe, oroxylum indicum and rhodomyrtus tomentosa; an in-vitro experiment shows that the traditional Chinese medicine preparation can remarkably inhibit the activity of hyaluronidase, also can inhibit the release of beta-HEX in an RBL-2H3 cell degranulation model, reduces the HIS level in a cell supernatant, and effectively improves the morphological abnormality caused by degranulation of RBL-2H3 cells; in-vivo experiments show that the traditional Chinese medicine preparation can significantly reduce behavioral scores of mice suffering from allergic rhinitis, inhibit expression of inflammatory factors TNF-alpha, serum Ig E and OVE-sIg E levels and HA concentration, reduce histopathologic changes caused by allergic rhinitis, effectively repair immune injuries of nasal mucosa of the mice and improve the curative effect of the mice. And a safe and effective new strategy is provided for the treatment of allergic rhinitis.

The use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-glisoquinolin-5-yl]-3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

The invention provides an anti-inflammatory polypeptide for inhibiting the activity of TNFa (Tumor Necrosis Factor a) protein. Specifically, skeleton polypeptide with the sequence of PIYLGGVFQ is modified, polypeptide with high affinity with TNFa protein and high inhibition rate on NO, IL-6 and degranulation rate is screened out from 11 modified polypeptides, and the polypeptide has high stability. In addition, compared with hormone anti-inflammatory drugs, the polypeptide provided by the invention has higher safety and can be used for preparing soothing anti-inflammatory drugs.

This invention provides a small molecule inhibitor targeting the FcεRIγ subunit and its application. It discovers that erythrophenol can act as a small molecule inhibitor targeting the FcεRIγ subunit, thereby inhibiting the occurrence of allergic reactions. This invention confirms the direct binding interaction between erythrophenol and the FcεRIγ subunit using SPR and CETSA techniques, revealing that erythrophenol can target and inhibit the FcεRIγ subunit. Furthermore, this invention finds that erythrophenol can significantly inhibit the release of IgE signal-induced β-aminoglycosidase in mast cells, exhibiting a significant ability to inhibit IgE signal-mediated mast cell degranulation and suppress mast cell activation-mediated allergic reactions. This fully demonstrates that erythrophenol, as an inhibitor targeting the FcεRIγ subunit, holds promise as the first inhibitor to induce FcεRIγ subunit degradation in anti-type I allergic diseases, and has broad application prospects for further use in anti-allergy treatment.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

The invention belongs to the technical field of food microorganisms, and particularly relates to a lactobacillus paracasei BHP06 with an anti-allergic function. The preservation number of the Lactobacillus paracasei BHP06 is GDMCC (China General Microbiological Culture Collection Center) No: 66270, and the preservation number of the Lactobacillus paracasei BHP06 is CGMCC No: 66270. The lactobacillus paracasei strain provided by the invention has good gastrointestinal tract reverse environment resistance and has good survival ability in simulated gastrointestinal fluid; good self-aggregation capability and hyaluronidase inhibition capability are realized. By establishing a degranulation model of RBL-2H3 cells, it is found that the strain can inhibit mast cell degranulation and relieve allergy; by establishing an RAW264.7 cell inflammation model, the strain disclosed by the invention is found to be capable of inhibiting allergic inflammatory reaction; by establishing an OVA (ovalbumin)-induced BALB / c mouse food allergy model, the strain disclosed by the invention is found to be capable of improving the anti-allergy ability of animals and exerting the activity of relieving food allergy.

The present invention discloses an interfering RNA of TPPP3 and its application, belonging to the field of biomedicine preparation technology. The present invention discloses the application of a preparation for inhibiting TPPP3 in the preparation of a drug for treating type I hypersensitivity reaction, the preparation comprising an siRNA that interferes with the expression of TPPP3, and the nucleotide sequence of the siRNA is as shown in SEQ ID NO: 5-6. The present invention knocks down the TPPP3 gene by RNAi technology, and finds that downregulating the expression of the TPPP3 gene can significantly inhibit IgE-mediated mast cell degranulation, and reduces the activity of upstream signal molecules of the FcεRI signaling pathway to regulate type I hypersensitivity reaction, providing an experimental basis and scientific basis for revealing the pathogenesis of type I hypersensitivity reaction and in-depth research on the role of TPPP3 in type I hypersensitivity reaction.

The invention provides a preparation process of an anti-allergic health food, and relates to the technical field of health food preparation. The production process of the anti-allergic health-care food comprises the following steps: preparing the following raw materials: herba cistanche, radix astragali, rhizoma polygonati, a bupleurum chinense leaf extract, a dandelion extract, honey and potassium sorbate, wherein the addition ratio of the bupleurum chinense leaf extract to the dandelion extract is 1: 2; cistanche deserticola, astragalus membranaceus and rhizoma polygonati are mixed, excessive water is added for soaking, reflux extraction and filtration are performed, filtrate is combined, and an extracting solution is obtained. By adding the bupleurum chinense leaf extract and the dandelion extract into an extracting solution of traditional Chinese medicinal materials such as astragalus membranaceus, the ratio of IgG1 / IgG2a can be effectively reduced, namely Th1 type immune response is relatively enhanced, Th2 type response is relatively weakened, allergen-specific IgE antibodies generated by B cells are correspondingly reduced, degranulation reaction and release of inflammatory mediators such as histamine are relieved, and the anti-inflammatory effect is achieved. The anaphylactic reaction is effectively relieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a compound in preparation of an anti-allergic medicine. The degranulation inhibition effect is verified through a mast cell in-vitro culture model, the overall anti-allergic activity is verified by combining an animal allergy model, and a series of experiments prove that the compound A33 can inhibit I-type anaphylaxis (such as ear and subcutaneous anaphylaxis) mediated by an IgE antibody. Different from a traditional anti-allergic drug (such as an antihistamine drug), the compound A33 is used for preventing release of media such as TNF-alpha and IL-6 from the source in an anaphylactic reaction starting link that the compound A33 directly inhibits mast cell degranulation in allusion to downstream blocking of an allergic medium, so that the compound A33 is introduced into the field of anti-allergic product research; a new candidate strategy with a clear targeting mechanism and an experimental basis is provided for prevention and / or treatment of allergic diseases, and the application value in anti-allergic drugs, cosmetics or daily chemical products is wide.

The application discloses application of a Corydalis yanhusuo extract in preparation of an anti-allergic drug and belongs to the technical field of anti-allergic drug preparation. The treatment effect of the drug on allergic diseases is evaluated by comparing P815 cell degranulation and inflammatory factor release, the inflammatory infiltration degree of a local skin allergic reaction of a mouse, and the allergic symptoms of a mouse as a whole, so that it is determined that the Corydalis yanhusuo extract can be used for preparation of an anti-allergic drug. The Corydalis yanhusuo extract can effectively alleviate the local and systemic allergic reaction symptoms of a mouse, and reduce mast cell degranulation, and has a significant improvement effect on symptoms caused by allergic reactions.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of a compound in preparation of an anti-allergic reaction medicine. The compound provided by the invention can effectively inhibit mast cell degranulation so as to inhibit generation of IgE-mediated I-type anaphylaxis, so that the compound is used as an anti-drug anaphylaxis preparation to provide more possible treatment schemes for clinical drug anaphylaxis treatment.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

This invention discloses an antipruritic gel containing 3-hydroxydecanoic acid microemulsion and its preparation method. The gel combines the natural antipruritic ingredient 3-hydroxydecanoic acid and peppermint oil. By preparing it into a microemulsion form, nano-sized droplets are combined with skin absorption enhancers and gel sustained-release agents, thereby improving transdermal absorption efficiency and prolonging the residence time in the skin to achieve a long-lasting antipruritic effect. 3-hydroxydecanoic acid exerts its antipruritic effect through anti-inflammatory action, blocking pruritus signaling pathways, and reducing mast cell degranulation. This antipruritic gel is stable at room temperature, easy to use, and suitable for relieving skin itching caused by mosquito bites, histamine, or non-histamine substances.

The application provides a kind of low sensitization of penaeus vannamei and its preparation method and application, belong to food biotechnology field.The application uses fucoidan to treat penaeus vannamei by covalent modification, after treatment, protein spatial conformation has changed significantly, allergen epitope is hidden.After BALB / c mouse sensitization model and RBL-2H3 cell degranulation model test shows, the sensitization of covalent modification penaeus vannamei decreases by 72.88%, low sensitization penaeus vannamei can inhibit mast cell degranulation and increase the threshold of sensitization, but still has immunogenicity.Through the construction of BALB / c mouse oral tolerance model, it is found that low sensitization penaeus vannamei can significantly alleviate the multiple immunoglobulin-mediated hypersensitivity caused by mouse allergy, which proves that low sensitization penaeus vannamei has auxiliary effect on oral tolerance, can promote oral tolerance ability, can be used as an effective immune tolerance agent for shrimp allergy patients.

The present application provides a dendrobium officinale polysaccharide extract, a preparation method and an application, the dendrobium officinale polysaccharide extract is with dendrobium officinale stem as raw material, is extracted by purified water reflux, is precipitated by ethanol, is deproteinized by Sevag, is decolorized and is deashed and is obtained by gel / film separation and purification, the mass percentage content of polysaccharide in the extract is 50-95wt%, the average molecular weight is 10-300 kDa, and the monosaccharide component includes mannose, glucose, galactose, fucose, rhamnose and arabinose.The dendrobium officinale polysaccharide extract provided by the present application has immune activation effect on natural killer cells, can promote the NK cell CD107a degranulation reaction and the expression of IFN-gamma, perforin and granzyme B in a dose-dependent manner, up-regulates the NKG2D related pathway, thereby activating the NK cell function and enhancing the killing activity of NK cells on tumor target cells such as K562.

The invention relates to application of bornyl acetate and an external gel preparation thereof in preparation of a medicine for relieving or treating chronic pruritus. Compared with the prior art, the bornyl acetate separated from volatile components of the folium artemisiae argyi supercritical extract has remarkable effects of inhibiting mast cell degranulation and inhibiting expression of pruritus-related factors at a cellular level and an animal level, and can be used for remarkably relieving mouse skin injury caused by DNCB; the polypeptide has the advantages of good safety, high selection index and the like, can be used for developing drugs for relieving and / or treating chronic itching and expanding treatment schemes of chronic itching, and has wide application prospects and important clinical significance.

The application discloses application of TPPP3 as an action target in preparation of a type I hypersensitivity reaction drug, and belongs to the technical field of biological medicine preparation.The application discloses application of an inhibitor of TPPP3 in preparation of a type I hypersensitivity reaction drug, wherein the inhibitor comprises siRNA interfering with gene expression of TPPP3 and / or Indibulin.The application knocks down the TPPP3 gene through RNAi technology, finds that deletion of the TPPP3 gene can significantly inhibit IgE-mediated mast cell degranulation, and reduces activity of an upstream signal molecule of an Fc epsilon RI signal pathway to regulate the type I hypersensitivity reaction, and also finds that Indibulin can inhibit RBL-2H3 cell degranulation in vitro, and can inhibit a PCA reaction in a mouse in vivo, indicating that the Indibulin has a treatment potential for type I hypersensitivity reaction diseases.

This disclosure provides medicaments and methods for treating envenomation using small molecule inhibitors of secretory phospholipase A2 (sPLA2). The sPLA2 inhibitor AZD2716 and related compounds can be used as monotherapy. Alternatively, the sPLA2 inhibitor varespladib and / or methyl varespladib can be used in combination with a statin. When a subject has been envenomed (for example, by a snake bite or bee sting), the medicaments can be administered to prevent lethal effects or tissues damage cause by the venom: for example, acute kidney injury, mast cell degranulation, or cerebral edema. The medicaments may be contained in an automatic injection device or an injection pen to deliver an effective dose as soon as possible following envenomation.

It is disclosed BTN3A inhibitory antibodies for use in treating gastro-intestinal inflammatory disorders, such as inflammatory bowel disease. The disclosure more specifically relates to specific anti-BTN3A antibodies that specifically bind to BTN3A and inhibit the degranulation of Vγ9 / Vδ2 T cells and their use in the manufacturing of novel drugs for use in treating gastro-intestinal inflammatory disorders such as ulcerative colitis and Crohn's disease.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

This invention relates to the extraction of oleanane-type compound neopentane triterpenoid B from *Bupleurum chinense*, its extraction method, and its application. It effectively solves the extraction and application problems of *Bupleurum chinense*. The technical solution is as follows: The chemical structural formula of the oleanane-type compound neopentane triterpenoid B is shown below. This invention extracts compounds from *Bupleurum chinense*, isolating the oleanane-type compound neopentane triterpenoid B. Related activity experiments show that neopentane triterpenoid B can significantly reduce C48 / 80-induced degranulation damage in RBL-2H3 cells, significantly reduce IgE levels, and has anti-allergic activity. It can be further used to prepare drugs for treating allergic diseases, thus expanding the medicinal value of *Bupleurum chinense*.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating allergic rhinitis and a preparation method of the traditional Chinese medicine composition. 5 to 20 parts of astragalus polysaccharide; 2 to 8 parts of glycyrrhizin; 1 to 5 parts of ceramide; 3-10 parts of a radix angelicae dahuricae extract; 3-10 parts of a cocklebur fruit extract; 5 to 15 parts of baicalin; and 1-5 parts of magnolia flower volatile oil. Wherein the active component of the supercritical extract of the coptis chinensis paste can correct proportional imbalance of immune cells from a transcriptional level, and can also cooperate with baicalin to inhibit phosphorylation and nuclear translocation of related signal pathways, inhibit effector cell activation degranulation and reduce expression and secretion of proinflammatory factors; the fructus xanthii extract and the flos magnoliae volatile oil can quickly relieve acute allergy symptoms, and the plant ceramide repairs the physical barrier of nasal mucosa in a targeted manner, so that the problems that in the prior art, a modern conversion process of a classic prescription is difficult in quality control, the preparation lacks local targeting, and the research on a compound mechanism is shallow are solved.

The invention provides a dendrobium officinale polysaccharide extract as well as a preparation method and application thereof.The dendrobium officinale polysaccharide extract is prepared from dendrobium officinale stems as a raw material through purified water reflux extraction, ethanol precipitation, Sevag deproteinization, decoloration and deliming and gel / membrane separation and purification, the mass percentage content of polysaccharide in the extract is 50-95 wt%, the average molecular weight is 10-300 kDa, and the content of polysaccharide in the extract is 50-95%. The monosaccharide components comprise mannose, glucose, galactose, fucose, rhamnose and arabinose. The dendrobium officinale polysaccharide extract provided by the invention has an immune activation effect on natural killer cells, can dose-dependently promote the degranulation reaction of NK cells CD107a and the expression of IFN-gamma, perforin and granzyme B, and up-regulate NKG2D related pathways, so that the functions of the NK cells are activated, and the killing activity of the NK cells on tumor target cells such as K562 is enhanced.

The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a Hangzhou thistle extract for treating atopic dermatitis (AD), and the Hangzhou thistle extract is prepared by the following steps: weighing Hangzhou thistle, adding an alcoholic solution for extraction, adsorbing and eluting an extracting solution by using resin, and collecting eluent to obtain the Hangzhou thistle extract. When the Hangzhou thistle extract provided by the invention is externally applied to a skin lesion part, AD symptoms can be effectively improved, including improvement of skin tissue form, promotion of skin lesion part recovery, reduction of scratching times, reduction of ear swelling degree and spleen index, reduction of inflammatory factor level, reduction of mastocyte number and inhibition of degranulation of mastocyte; the inflammatory response of atopic dermatitis is improved by regulating and controlling a TLR4 / NF-kappa B pathway. The problem of poor patient compliance caused by tedious operation of traditional Chinese medicine compound oral administration is solved. A novel, effective and safe treatment mode is provided for AD treatment, application and development of Hangzhou thistle are greatly promoted, and a new strategy is provided for local resource development and utilization and economic development.

The application provides a cell identification kit and a use method and application thereof in identifying mast cells, and relates to the technical field of cell identification. The cell identification kit comprises CD117 antibody conjugated magnetic microparticles, CD16 antibody conjugated magnetic microparticles and Fc epsilon R1 alpha antibody conjugated magnetic microparticles, and FcR blocking agent and eluent. The cell identification kit can be used to identify one or more of CD117, Fc epsilon R1 alpha and CD16 on the surface of cells, and target cells with a purity of at least 90% can be obtained. The application is applied to identifying whether a cell is CD117 + Fc epsilon R1 alpha + CD16 ‑ mast cells, target cells with a purity higher than 95% can be obtained, the degranulation rate of mast cells is improved, and the technical problem of a low degranulation rate of mast cells obtained by a mast cell identification method in the prior art is solved.

Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enriched tumor reactive TILs for treating cancer in a human or other subject. Among the provided embodiments of TIL compositions may include those that exhibit substantial tumor reactivity activity, including degranulation and the ability to express one or more of IFN-gamma and TNF-alpha, in response to antigen presenting cells presenting neo antigenic peptides.

Various aspects of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched for tumor-reactive cells, methods for producing TILs enriched for tumor-reactive cells, and methods and uses of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. Among the provided aspects of the TIL compositions can be TIL compositions that exhibit substantial tumor-reactive activity, including degranulation and the ability to express one or more of IFN-γ and TNF-α in response to antigen-presenting cells that present neo-antigenic peptides. TIFF2025537148000002.tif51170

The invention belongs to the technical field of exosome application, and discloses application of a sarcodon aspratus exosome in preparation of a medicine for treating interstitial cystitis. The prepared sarcodon aspratus exosome is perfused into the bladder of a rat with interstitial cystitis, and it is found that the sarcodon aspratus exosome can significantly improve urination disorder of the model rat and relieve symptoms of interstitial cystitis. In addition, the invention also finds that (1) the sarcodon aspratus exosome can obviously reduce the expression of IL-1beta, IL-6, MCP-1, CXCL-1, ICAM-1 and BAX in the bladder tissue; (2) the sarcodon aspratus exosome can significantly reduce the activation number of mast cells and inhibit degranulation of the mast cells; and (3) the sarcodon aspratus exosome can significantly improve epithelial cell apoptosis. The research shows that the sarcodon aspratus exosome can be used for treating interstitial cystitis. The research provides a new idea for the treatment of interstitial cystitis.

The application discloses a new water-soluble phenolic acid salviamarinic acid B extracted from radix salviae miltiorrhizae, adopts a C48 / 80 induced RBL-2H3 cell degranulation in vitro model to simulate the degranulation phenomenon of mast cells in vitro, and first separates and identifies a new water-soluble phenolic acid compound (salviamarinic acid B) from the ethyl acetate part of radix salviae miltiorrhizae, which can inhibit the release of beta-Hex, reduce the levels of mMCP-1, beta-MCT, HIS and LTC4, significantly improve the degranulation phenomenon of RBL-2H3 cells, has significant anti-asthma activity, and has significant social and economic benefits.

Methods to purposefully target lytic granules to the cell membrane following NK cell activation for the benefit of bystander killing in a solid tumor setting as novel cell therapy approach. These methods can be used alone or in combination with dispersion related strategies. Methods of using truncated proteins from the dynein-dynactin complex to block dynein function to induce lytic granule dispersion. The methods and compositions enhance the lethality of degranulation events. The methods and compositions can boost cytotoxicity in a solid tumor directly or be combined with other technologies, such as immunotherapies to improve their outcomes.